Skip to main content
Delfa

← All trials/NCT06501326

UnknownPhase 4

Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease

Clinical Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism-associated Fatty Liver Disease (MAFLD)

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Estimated enrollment

102

Study population

MASH / NAFLD / liver fibrosis, Obesity / overweight

Eligibility highlights

-

Primary endpoints

•Body weight•FABP4•BMI

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06501326
Org study IDliraglutide

Timeline

Milestones

Study start2023-11-01actual
Study first posted2024-07-15actual
Last update posted2024-07-15actual
Primary completion2024-10-31estimated
Study completion2025-02-28estimated

Assets

Investigational agents

Liraglutide

Who this study enrolls

MASH / NAFLD / liver fibrosisObesity / overweight

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Clinical diagnosis of Metabolic Associated Fatty Liver Disease(MAFLD);

2. Clinical diagnosis of Obesity.

Exclusion criteria

1. Medicated Hepatitis and Viral Hepatitis;

2. Have severe hepatic or renal insufficiency;

3. have used any weight-loss drug;

4. History of severe gastrointestinal disorders;

5. Malignant tumors, autoimmune diseases, hematologic diseases;

6. Psychopath;

7. Women who are pregnant, breastfeeding or preparing for pregnancy;

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
4
MASH / liver
2
Cardiometabolic biomarkers
1
Other (unclassified)
1

Weight & body composition

4 endpoints
Primary/protocol endpoint

Body weight

Time frame:Three months

descriptive, improvement

Primary/protocol endpoint

BMI

Time frame:Three months

descriptive, improvement

Secondary/protocol endpoint

Waist circumference,

Time frame:Three months

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

hip circumference

Time frame:Three months

change from baseline, improvement

MASH / liver

2 endpoints
Primary/protocol endpoint

LSM

Time frame:Three months

Liver stiffness (VCTE), change

change from baseline, improvement

Primary/protocol endpoint

CAP

Time frame:Three months

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint/low confidence

lipid indices

Time frame:Three months

change from baseline, improvement

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

FABP4

Time frame:Three months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.